Table 6.
COVID-19 status and serology measurement at baseline visit.
| Overall | Discovery cohort | Validation cohort | |||
|---|---|---|---|---|---|
| A. Status COVID-19 vaccination at baseline inclusion | |||||
| Fully vaccinated, N (%) | 259 (13.7%) | 237 (15.2%) | 22 (6.5%) | ||
| Positive S-serology measured at baseline visit | 257 (13.6%) | 235 (99.2%) | 22 (100%) | ||
| Negative S-serology measured at baseline visit | 2 (0.1%) | 2 (0.8%) | 0 (0%) | ||
| Vaccinated but not fully, N (%) | 213 (11.2%) | 161 (10.3%) | 52 (15.5%) | ||
| Vaccinated, but unknown how often or when, N (%) | 2 (0.1%) | 2 (0.1%) | 0 (0%) | ||
| Unvaccinated, N (%) | 1421 (75.0%) | 1159 (74.3%) | 262 (80.0%) | ||
| B. Previous COVID-19 infection at baseline inclusion | |||||
| Participant not exposed to COVID-19 (enrolled March 2020 or earlier), N (%) | 381 (20.1%) | 293 (18.8%) | 88 (26.2%) | ||
| Participants potentially exposed to COVID-19 (enrolled June 2020 or later), N (%) | 1514 (79.9%) | 1266 (81.2%) | 248 (73.8%) | ||
| Of participants exposed to COVID-19: | |||||
| At least one vaccination, N (%) | 474 (31.3%) | 400 (31.6%) | 74 (29.8%) | ||
| Evidence of past COVID-19 infection, N (%) | 55 (11.6%) | 47 (11.8%) | 8 (10.8%) | ||
| Reported previous positive PCR, N | 37 | 30 | 7 | ||
| Previous positive S-serology in own hospital before vaccination, N | 21 | 20 | 1 | ||
| No vaccination, N (%) | 1040 (68.7%) | 866 (68.4%) | 174 (70.2%) | ||
| Evidence of past COVID-19 infection, N (%) | 179 (17.2%) | 143 (16.5%) | 36 (20.7%) | ||
| Previous reported positive PCR, N | 40 | 32 | 8 | ||
| Previous positive S-serology in own hospital before vaccination, N | 30 | 30 | 0 | ||
| Positive S-serology at baseline visit, N | 175 | 141 | 34 | ||
S, anti-Spike protein; N, Number of Participants. COVID-19, Coronavirus Disease 2019; PCR, Polymerase Chain Reaction.